Anti-amyloid drugs for early Alzheimer’s disease, including lecanemab, are associated with adverse events (AEs), such as amyloid-related imaging abnormalities (ARIA)-edema/effusion (E), ARIA-hemorrhage, and infusion-related reactions, which can indicate allocated arms in clinical trials. Herein, we evaluated the predictive value of AEs using a meta-analysis to estimate their incidence and simulated positive predictive value (PPV). The PPV for ARIA-E was high (0.915), but that for ARIA hemorrhage was low (0.630). Infusion-related reactions had a high PPV of 0.910, but with a wide confidence interval. Our results suggest the need to ameliorate the unblinding effects of AEs, particularly ARIA-E in trials.
CummingsJ, AisenP, ApostolovaLG, et al.Aducanumab: Appropriate use recommendations. J Prev Alzheimers Dis2021; 8: 398–410.
2.
CummingsJ, ApostolovaL, RabinoviciGD, et al.Lecanemab: Appropriate use recommendations. J Prev Alzheimers Dis2023; 10: 362–377.
3.
Eisai. “LEQEMBI ® Intravenous Infusion” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan, https://www.eisai.com/news/2023/news202359.html (2023, accessed 25 September 2023).
CogswellPM, BarakosJA, BarkhofF, et al.Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: Detection and reporting recommendations for clinical practice. AJNR Am J Neuroradiol2022; 43: E19–E35.
9.
BarakosJ, PurcellD, SuhyJ, et al.Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with anti-amyloid beta therapy. J Prev Alzheimers Dis2022; 9: 211–220.
10.
Van GoolWA. Unblinding in the lecanemab trial in Alzheimer’s disease. Brain2023; 146: e100.
11.
WoltersFJandLabrecqueJA. Potential impact of unblinding on observed treatment effects in Alzheimer’s disease trials. Alzheimers Dement2024; 20: 3119–3125.
12.
BernaC, KirschI, ZionSR, et al.Side effects can enhance treatment response through expectancy effects: An experimental analgesic randomized controlled trial. Pain2017; 158: 1014–1020.
13.
HeySPandKimmelmanJ. The questionable use of unequal allocation in confirmatory trials. Neurology2014; 82: 77–79.
14.
Budd HaeberleinS, AisenPS, BarkhofF, et al.Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis2022; 9: 197–210.
15.
SwansonCJ, ZhangY, DhaddaS, et al.A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther2021; 13: 80.
16.
van DyckCH, SwansonCJ, AisenP, et al.Lecanemab in early Alzheimer’s disease. N Engl J Med2023; 388: 9–21.
17.
MintunMA, LoAC, Duggan EvansC, et al.Donanemab in early Alzheimer’s disease. N Engl J Med2021; 384: 1691–1704.
18.
SimsJR, ZimmerJA, EvansCD, et al.Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA2023; 330: 512–527.
19.
EcclesR. Placebo and side effects confound clinical trials on new antitussives. Lung2021; 199: 319–326.
HonigLS, BarakosJ, DhaddaS, et al.ARIA in patients treated with lecanemab (BANin a phase 2 study in early Alzheimer’s disease. Alzheimers Dement (N Y)2023; 9: e12377.
